Trial intelligence / Profile preview

ALBUCAP phase III trial of intravenous albumin in hospitalized adults with community-acquired pneumonia

2018-003117-18Phase 3Terminated

Sponsor: Dr. Jordi CarratalÃ FernÃ¡ndez (Servicio de Enfermedades Infecciosas) del Hospital Universitario de Bellvitge
Start: Apr 2019
Modality: Recombinant Proteins and Enzymes
Countries: 1

Overview

Phase 3, randomised, open-label trial of albumin (human) in community-acquired pneumonia (CAP) (2 arms), sponsored by Dr. Jordi CarratalÃ FernÃ¡ndez (Servicio de Enfermedades Infecciosas) del Hospital Universitario de Bellvitge. Primary endpoint: Number of patients achieving clinical stability on day 5. Started Apr 2019; status: terminated.

Drugs

albumin (human)

Conditions

community-acquired pneumonia (CAP)

Beyond the preview

Go deeper on 2018-003117-18.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2018-003117-18.